SG192911A1 - Aav -vectors for use in gene therapy of choroideremia - Google Patents

Aav -vectors for use in gene therapy of choroideremia Download PDF

Info

Publication number
SG192911A1
SG192911A1 SG2013063797A SG2013063797A SG192911A1 SG 192911 A1 SG192911 A1 SG 192911A1 SG 2013063797 A SG2013063797 A SG 2013063797A SG 2013063797 A SG2013063797 A SG 2013063797A SG 192911 A1 SG192911 A1 SG 192911A1
Authority
SG
Singapore
Prior art keywords
aav
vector
rep1
vector according
sequence
Prior art date
Application number
SG2013063797A
Other languages
English (en)
Inventor
Robert Maclaren
Miguel Seabra
Matthew John During
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43881504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG192911(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of SG192911A1 publication Critical patent/SG192911A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2013063797A 2011-02-22 2012-02-21 Aav -vectors for use in gene therapy of choroideremia SG192911A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1103062.4A GB201103062D0 (en) 2011-02-22 2011-02-22 Method
PCT/GB2012/050376 WO2012114090A1 (en) 2011-02-22 2012-02-21 Aav -vectors for use in gene therapy of choroideremia

Publications (1)

Publication Number Publication Date
SG192911A1 true SG192911A1 (en) 2013-09-30

Family

ID=43881504

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013063797A SG192911A1 (en) 2011-02-22 2012-02-21 Aav -vectors for use in gene therapy of choroideremia

Country Status (18)

Country Link
US (4) US9834788B2 (cg-RX-API-DMAC7.html)
EP (2) EP2678435B2 (cg-RX-API-DMAC7.html)
JP (4) JP2014512171A (cg-RX-API-DMAC7.html)
KR (3) KR102299430B1 (cg-RX-API-DMAC7.html)
CN (2) CN107881198A (cg-RX-API-DMAC7.html)
AU (2) AU2012220404B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013021318B1 (cg-RX-API-DMAC7.html)
CA (1) CA2827975C (cg-RX-API-DMAC7.html)
DK (1) DK2678435T3 (cg-RX-API-DMAC7.html)
ES (1) ES2676550T5 (cg-RX-API-DMAC7.html)
GB (1) GB201103062D0 (cg-RX-API-DMAC7.html)
HK (2) HK1258917A1 (cg-RX-API-DMAC7.html)
IL (1) IL228031B (cg-RX-API-DMAC7.html)
MX (2) MX356525B (cg-RX-API-DMAC7.html)
PL (1) PL2678435T3 (cg-RX-API-DMAC7.html)
PT (1) PT2678435T (cg-RX-API-DMAC7.html)
SG (1) SG192911A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012114090A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103062D0 (en) † 2011-02-22 2011-04-06 Isis Innovation Method
CN105980569A (zh) 2013-08-05 2016-09-28 莱顿大学医学中心附属莱顿教学医院 重组aav-crumbs同源物组合物及治疗lca-8和进行性rp的方法
KR102281881B1 (ko) * 2013-12-06 2021-07-27 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US20180043034A1 (en) * 2015-03-06 2018-02-15 Massachusetts Eye And Ear Infirmary Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene
CN109069668B (zh) 2015-12-14 2023-04-18 宾夕法尼亚州大学信托人 用于眼病的基因疗法
GB201604146D0 (en) 2016-03-10 2016-04-27 Nightstarx Ltd Prenylation assay
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
US10633689B2 (en) 2016-11-07 2020-04-28 Spark Therapeutics, Inc. Rab Escort Protein potency assay
US11938197B2 (en) * 2017-01-10 2024-03-26 The Sydney Children's Hospitals Network (Randwick And Westmead (Incorporating The Royal Alexandra Hospital For Children) Polynucleotides and vectors for the expression of transgenes
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
US11827898B2 (en) 2017-06-14 2023-11-28 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
MX2020004005A (es) * 2017-10-03 2020-10-05 Prevail Therapeutics Inc Terapias genicas para los trastornos lisosomales.
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018352986A1 (en) 2017-10-17 2020-05-14 Nightstarx Limited Prenylation assay
KR20200119782A (ko) * 2017-12-06 2020-10-20 오비드 테라퓨틱스 인크. 발작 장애 치료 시 mir101 또는 mir128의 용도
WO2019152841A1 (en) 2018-02-01 2019-08-08 Homology Medicines, Inc. Adeno-associated virus compositions for pah gene transfer and methods of use thereof
AU2019215152A1 (en) 2018-02-01 2020-08-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
US11306329B2 (en) 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
EP3775234A1 (en) * 2018-04-05 2021-02-17 NightstaRx Limited Aav compositions, methods of making and methods of use
AU2018422759B2 (en) * 2018-05-07 2026-01-22 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US20220193261A1 (en) * 2019-04-30 2022-06-23 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of pompe disease
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復pah基因功能的腺相關病毒組成物及其使用方法
IL300526A (en) 2020-08-17 2023-04-01 Massachusetts Inst Technology Approaches to SHANK3 gene therapy
WO2022109247A1 (en) 2020-11-20 2022-05-27 Biogen Ma Inc. Viral vector potency assay
EP4482970A1 (en) 2022-02-23 2025-01-01 Massachusetts Institute of Technology Methods for upregulating shank3 expression
JP2025528188A (ja) 2022-08-11 2025-08-26 インスティテュート オブ モレキュラー アンド クリニカル オフサルモロジー バーゼル (アイオービー) ヒト錐体光受容体オプトジェネティクス構築物
AU2023323327A1 (en) 2022-08-11 2025-02-13 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Promoters for specific expression of genes in cone photoreceptors
CN121794288A (zh) 2023-05-05 2026-04-03 麻省理工学院 Shank3基因治疗方法
WO2025090942A1 (en) * 2023-10-26 2025-05-01 University Of Notre Dame Du Lac Gene therapy for treatment of neurometabolic disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856585A1 (en) 1997-01-29 1998-08-05 Introgene B.V. A conditional replication and expression system
EP1228234A2 (en) * 2000-03-14 2002-08-07 Neurologix, Inc. Production of chimeric capsid vectors
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
US20040208847A1 (en) * 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
WO2006090689A1 (ja) * 2005-02-23 2006-08-31 Dnavec Corporation Siv-pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬
AU2006242371A1 (en) * 2005-04-29 2006-11-09 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of nucleic acid at post-transcriptional level
US20090022731A1 (en) * 2006-08-25 2009-01-22 Wyeth Arthritis-associated B cell gene expression
US20100278843A1 (en) * 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
EP2242840B1 (en) * 2008-01-29 2019-07-24 Applied Genetic Technologies Corporation Recombinant adeno-associated virus production using bhk cells in suspension
CA2713755A1 (en) * 2008-02-07 2009-08-13 Ceregene, Inc. Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein
SI3988660T1 (sl) * 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
GB201103062D0 (en) † 2011-02-22 2011-04-06 Isis Innovation Method

Also Published As

Publication number Publication date
CA2827975A1 (en) 2012-08-30
US20140107185A1 (en) 2014-04-17
WO2012114090A1 (en) 2012-08-30
CN103562396A (zh) 2014-02-05
PL2678435T3 (pl) 2018-11-30
EP2678435A1 (en) 2014-01-01
EP2678435B2 (en) 2024-02-07
US20230332176A1 (en) 2023-10-19
BR112013021318B1 (pt) 2021-12-07
ES2676550T5 (es) 2024-06-27
US20180135078A1 (en) 2018-05-17
MX2013009604A (es) 2013-09-16
MX388146B (es) 2025-03-19
KR20210112407A (ko) 2021-09-14
KR102299430B1 (ko) 2021-09-07
JP2023036618A (ja) 2023-03-14
IL228031A0 (en) 2013-09-30
DK2678435T3 (en) 2018-08-27
KR102139203B1 (ko) 2020-07-29
BR112013021318A2 (pt) 2016-10-25
EP3428283A1 (en) 2019-01-16
JP2014512171A (ja) 2014-05-22
IL228031B (en) 2018-02-28
GB201103062D0 (en) 2011-04-06
CA2827975C (en) 2023-06-13
AU2012220404B2 (en) 2017-04-20
CN107881198A (zh) 2018-04-06
KR20140044793A (ko) 2014-04-15
HK1258917A1 (en) 2019-11-22
US9834788B2 (en) 2017-12-05
HK1249548A1 (zh) 2018-11-02
AU2012220404A1 (en) 2013-09-12
PT2678435T (pt) 2018-07-17
JP2020054345A (ja) 2020-04-09
EP2678435B1 (en) 2018-05-16
MX356525B (es) 2018-06-01
KR20200092422A (ko) 2020-08-03
AU2017206254A1 (en) 2017-08-10
ES2676550T3 (es) 2018-07-20
JP2017221192A (ja) 2017-12-21
US20210032656A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US20230332176A1 (en) Aav-vectors for use in gene therapy of choroideremia
JP7713130B2 (ja) 遺伝性難聴の処置のためのアデノ随伴ウイルス(aav)システム
KR20180137511A (ko) β-사르코글리칸 및 마이크로RNA-29의 아데노-관련 바이러스 벡터 전달 및 근이영양증의 처리
US20250049949A1 (en) Gene therapy for lamin a-associated deficiencies
JP2024542950A (ja) Cdkl5欠損症(cdd)の治療において有用な組成物
US20240384297A1 (en) Gene therapy construct for treating pompe disease, pharmaceutical composition, and method
WO2024220722A1 (en) Compositions and methods for tissue- specific expression of gene therapies
HK1191672A (en) Aav-vectors for use in gene therapy of choroideremia
HK1191672B (en) Aav-vectors for use in gene therapy of choroideremia
US12605465B2 (en) AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB
HK40126715A (en) Adeno-associated virus vector delivery of muscle-specific micro-dystrophin to treat muscular dystrophy
TW202525313A (zh) 用aav基因治療載體及治療調配物治療肥厚性心肌病之方法